Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT07169942

Obesity & weight · Phase 2 · Active, not recruiting

Aleniglipron Phase 2 Body Composition Study

NCT07169942 · Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

What this trial means for you

This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying aleniglipron or placebo for obesity, overweight, or chronic weight management.

Who can joinAll sexes, 18 Years – 79 Years
Healthy volunteersNo — diagnosis required
What you'd takealeniglipron or placebo
Study length~12 months overall
Planned participants71
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Signed informed consent * Participants age ≥18 years and \<80 years, with BMI ≥30 kg/m2 * Screening HbA1c \<6.5 % Exclusion Criteria: * Previous documented diagnosis of diabetes mellitus * Self-reported change in body weight \>5% within 3 months before Screening * Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA study specific manual that allows hemi-scan * Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening) * Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)

Study sites by state

Arizona

  • Research Site — Phoenix

Illinois

  • Research Site — Chicago

Minnesota

  • Research Site — Richfield

Missouri

  • Research Site — City of Saint Peters

New York

  • Research Site — Rochester

North Carolina

  • Research Site — Wilmington

Oklahoma

  • Research Site — Norman

South Carolina

  • Research Site — Moncks Corner
  • Research Site — North Charleston

Texas

  • Research Site — Austin
  • Research Site — San Antonio

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth